AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02800733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffron
Description: 20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
Study NCT02800733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 20 patients with mild to moderate GAD who receive sertraline will receive placebo too
Study NCT04037228 — intervention group
Intervention type: DEVICE
Intervention: KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)
Description: The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
Study NCT04086355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oromotor exercises and neuromuscular electrical stimulations
Description: treatment study group with occupational exercises and electrical stimulation
Study NCT03461939 — intervention group
Intervention type: OTHER
Intervention: ePRIME symptom monitoring tool
Description: ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
Study NCT03264144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norms campaign
Description: Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
Study NCT06043336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, granisetron & palonosetron
Description: . Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
Study NCT06043336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, granisetron & palonosetron
Description: . Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
Study NCT02448199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam and Glucosamine
Description: Experimental
Study NCT02448199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Active Comparator
Study NCT02448199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine
Description: Active Comparator
Study NCT00181844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
Study NCT03790644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton assist
Description: A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community.
Study NCT01605669 — intervention group
Intervention type: OTHER
Intervention: Tranthoracic Echocardiogram
Description: standard measurement
Study NCT01605669 — intervention group
Intervention type: DEVICE
Intervention: Cardiac Ascultation Recordings with Electronic stethoscope
Description: 3M device
Study NCT00678730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: 0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Study NCT00678730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: delta 9 tetrahydrocannabinol
Description: 0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Study NCT01610297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670
Description: Oral dose of ICL670 at 10 mg/kg daily
Study NCT04502901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX0826
Description: investigational AR antagonist
Study NCT02453009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02453009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Pharmaceutical form:solution Route of administration: intravenous
Study NCT02453009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02507154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + NK cells
Study NCT01554098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy : Supine first
Description: The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
Study NCT01554098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strategy : dynamic first
Description: The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
Study NCT02453009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02453009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Pharmaceutical form : soft gelatin capsules Route of administration: oral
Study NCT00631852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: American Ginseng root
Description: four, 250mg tablets daily 5-14 days prior to surgery
Study NCT00833352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT-D Therapy
Description: Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
Study NCT00833352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D Therapy
Description: Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
Study NCT06125496 — intervention group
Intervention type: OTHER
Intervention: Pain management
Description: Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
Study NCT04502901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of KX-826
Study NCT02639910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
Study NCT02639910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: idelalisib dose: 150 mg twice daily orally
Study NCT02639910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: venetoclax dose: 400 mg once daily orally
Study NCT00359242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Sleeping and Soothing
Description: Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
Study NCT00359242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated Food Exposure
Description: Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
Study NCT01825122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Study NCT02648503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Description: Using rocuronium and reversal with sugammadex
Study NCT01825122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01857765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Range of motion stretching exercises
Study NCT01857765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Follow-up with surgeon's clinic
Study NCT02648503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular block
Description: Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
Study NCT01857765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up
Description: Follow-up with surgeon's clinic
Study NCT01869478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Thrombolysis
Study NCT01869478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Arterial Reperfusion
Study NCT03326674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel and Capecitabine
Description: Tesetaxel plus reduced dose of Capecitabine
Study NCT03326674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine alone at approved dose
Study NCT00408564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00408564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00408564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00408564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00408564 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00408564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT04221607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensate Focus exercise
Description: Structured exercise to enhance intimacy
Study NCT04815421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the paste group
Description: Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
Study NCT04815421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the meridian group
Description: Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
Study NCT03660436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days
Study NCT03660436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Specified dose on specified days
Study NCT03359577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psorax35
Description: This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
Study NCT03359577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCT oil
Description: This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
Study NCT02721836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
Study NCT02721836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counselling
Description: Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
Study NCT02494050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation-Full
Description: Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
Study NCT02494050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation-Short
Description: Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
Study NCT04149808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Ag (burn dressing)
Description: Dressing for low to medium exuding burns and wounds.
Study NCT04149808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform Dressing
Description: Standard of care dressing for low to medium exuding burns and wounds.
Study NCT02494050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Disorder Collaborative Care
Description: This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
Study NCT03313830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Hydrolysate (WPH)
Description: Subjects will ingest WPH on one occasion.
Study NCT03313830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intact Whey Protein (WHEY)
Description: Subject will ingest WHEY on another occasion.
Study NCT04709510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex Ultrasound
Description: Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
Study NCT00945659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Sensor
Description: Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
Study NCT00945659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
Study NCT00945659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CGS + Behavior Therapy
Description: Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
Study NCT04153747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)
Description: Pulmonary veins electrical isolation: high-power and short-duration ablation
Study NCT04153747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values
Description: Pulmonary veins electrical isolation: low-power ablation.
Study NCT04153747 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal endoscopy
Description: Esophageal endoscopy to detect postablation esophageal thermal lesions.
Study NCT04153747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal endoscopy
Description: Esophageal endoscopy to detect postablation esophageal thermal lesions.
Study NCT04153747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Daily 30-seconds ECG
Description: Transtelephonic daily 30-seconds single lead electrocardiogram
Study NCT04153747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Daily 30-seconds ECG
Description: Transtelephonic daily 30-seconds single lead electrocardiogram
Study NCT01104675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 275 mg (or 250 mg for BSA \< 1.65) per day in oral capsules in 28 day continuous cycles
Study NCT01088659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly, 96 weeks
Study NCT01088659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: orally daily, 96 weeks
Study NCT01088659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: 245mg po daily, 96 weeks
Study NCT02578836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fogel Gastroplasty
Description: The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
Study NCT01842945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) without therapist contact.
Description: The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
Study NCT01842945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (iCBT) with therapist contact.
Description: The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
Study NCT03352024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Relational care
Description: Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
Study NCT03352024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypno-analgesia
Description: Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))